Interleukin-2-mediated CD4 T-cell activation correlates highly with effective serological and T-cell responses to SARS-CoV-2 vaccination in people living with HIV.

Interleukin-2-mediated CD4 T-cell activation correlates highly with effective serological and T-cell responses to SARS-CoV-2 vaccination in people living with HIV.

Publication date: Aug 01, 2024

People living with HIV (PLWH) despite having an appreciable depletion of CD4 T-cells show a good severe acute respiratory syndrome coronavirus 2 vaccination response. The underlying mechanism(s) are currently not understood. We studied serological and polyfunctional T-cell responses in PLWH receiving anti-retroviral therapy stratified on CD4 counts as PLWH-high (CD4 ≥ 500 cells/mm) and PLWH-low (

Concepts Keywords
Cd4500cells Adult
Effective Antibodies, Neutralizing
Hiv Antibodies, Neutralizing
Therapy Antibodies, Viral
Vaccination Antibodies, Viral
CD4 Lymphocyte Count
CD4-Positive T-Lymphocytes
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
COVID‐19
cytokine
Female
HIV Infections
Humans
Immunoglobulin G
Immunoglobulin G
Interleukin-2
Interleukin-2
Lymphocyte Activation
Male
Middle Aged
SARS-CoV-2
serology
T cell
Vaccination
vaccine

Semantics

Type Source Name
disease VO effective
disease IDO cell
disease VO vaccination
disease VO Severe acute respiratory syndrome coronavirus 2
disease MESH COVID-19
disease MESH HIV Infections
disease VO vaccine

Original Article

(Visited 2 times, 1 visits today)